about
The platelet count in EDTA-anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories.Platelet transfusion strategy for hematologic cancers.Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patientsAddressing the management of atrial fibrillation - a systematic review of the role of dronedarone.New approaches for measuring coagulation.State of the art of new P2Y12 antagonists.Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons.Primary autoimmune neutropenia in adults: case report and review of the literature.Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes.Inherited dysfunctional platelet P2Y12 receptor mutations associated with bleeding disorders.Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal.Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patientsBleeding risk of surgery and its prevention in patients with inherited platelet disordersRosiglitazone plus metformin to prevent type 2 diabetes mellitus.Effects of 5'-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors.In vitro variations of Mean platelet volume over time in blood samples collected in different anticoagulants from thrombocytopenic patients and healthy subjects.Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry.Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.To anticoagulate or not to anticoagulate? That is the question : A Medline-based quantitative approach to share evidence on common clinical problems.Wrong guidelines: how to detect them and what to do in the case of flawed recommendationsBleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiencyMegakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndromeANKRD26-related thrombocytopenia and myeloid malignanciesAbnormalities of homocysteine and B vitamins in the nephrotic syndromeAcute renal failure in a single kidney with previous obstructionAspirin for the primary prevention of cardiovascular diseasesOff-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosisEV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirinIs perioperative bridging anticoagulation useful in patients with atrial fibrillation?Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studiesHigh on treatment platelet reactivity as a risk factor for adverse left ventricular remodelling after STEMICurrent and emerging approaches for evaluating platelet disordersAggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapyOral anticoagulants for stroke prevention in patients with atrial fibrillation and previous intracranial hemorrhageThrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic reviewAn "unmodifiable" risk factor that has been modified[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]
P50
Q33401669-E84F4F80-B00E-4DA3-8F87-477084066977Q33418477-308EE566-1251-44CE-97DB-6EDA12D91A34Q33430809-6A22231C-A014-40DA-8E0F-5E74A19DEA23Q36026806-7EE81769-B6E2-42B4-88E2-10E529F8D025Q36473061-63222E71-F6E0-4E02-8E12-21E6A4548322Q37697014-AFFDECE5-0189-4BE7-A094-9199124F63FFQ38131425-D643B616-5250-4E83-A242-84D62BB3F9CEQ38211687-FA442FFC-A28F-4A41-B9CD-AB16E4693C3BQ38875635-FBB1C309-0C98-43B1-9A50-3F67FBF94678Q38917291-8359A7B2-C998-4634-9660-CC7C537FA6E4Q39140565-A1E02A10-417F-487B-A6D7-6E046EC8B2EDQ40793665-A6613CE7-440B-44AE-904E-6F13D9E76BE4Q41480992-CF890E93-AF5C-4BD4-B6B3-A807A0649E22Q42849390-7090E0EB-FD19-4FD8-91B1-01CAFC44B1A5Q46436392-8C7575C6-197D-4822-8B52-15FAB596C041Q48224133-97CAE657-1A27-4B99-8CE6-730F01CBA48AQ50528955-9EEEEDFE-12BC-4AEB-81F8-607398DD6B09Q51134013-0B0E72A0-A658-4CE5-956F-515E7FA8502CQ53018135-E8CA8FDD-AACB-4D83-B5BD-E0D23E58950CQ53973148-A5840D45-859A-4F83-973F-01692EE1022BQ56961081-07EACFB4-36F8-4F1A-8161-C5A4EC2839C0Q57235128-9F776A1C-7696-415A-AF7F-39198DE59FF2Q57589280-99EC8B60-CC56-4FB0-ACA4-82E04438BD07Q57589329-924A72FB-A4DA-4A15-8D8B-CDEEA377E07BQ60729413-C94BDF42-9F93-4CBD-9FDB-2329ECF6C915Q60729432-6550758A-0C82-46F5-9D4F-041C8C71FC75Q62072511-277BA5E8-1219-405D-B780-B5A96543574DQ84032123-6243B8F3-CF42-4DFD-9D05-8372150FA125Q84949488-ECBA5B93-005D-4A76-8F98-A5632B44AB3EQ86897346-BCC68A8D-AD9C-4302-A76F-88D5AC8BED8FQ86912459-4E4DB872-8BC8-40CF-BDCC-847A2AB0F077Q87704356-E15A9AB0-D48E-438F-B9E4-97A4F867872AQ87924348-F43DDE7D-5080-42B8-AC42-87E9E966F374Q88051739-7FB81EFC-16F9-4F1B-80C9-66857B3D20A4Q88691325-27279C97-5627-4952-A4C8-5D57D93518E0Q91850955-573F9ECB-766B-4660-9004-6501EF811554Q92515594-7C70971A-804C-4E98-B10C-8CFCD80C5271Q95496907-B399A302-A118-4846-BE75-770AE9BF2DF6
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
研究者
@zh
name
GianMarco Podda
@ast
GianMarco Podda
@en
GianMarco Podda
@es
GianMarco Podda
@nl
type
label
GianMarco Podda
@ast
GianMarco Podda
@en
GianMarco Podda
@es
GianMarco Podda
@nl
prefLabel
GianMarco Podda
@ast
GianMarco Podda
@en
GianMarco Podda
@es
GianMarco Podda
@nl
P106
P1153
56785702900
P31
P496
0000-0002-1791-8905